Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.

After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.

The 2024 AACR abstract title drop features several noteworthy clinical studies.

Of the big oncology deals since 2016, there are still plenty that could go either way.

Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.

The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.